Effects of a therapy with losartan and quinaprilat on the progression of chronic renal failure in rats after a single dose of uranyl nitrate or 5/6 nephrectomy

Experimental and Toxicologic Pathology

Volumn 54, Issue 5-6, 2003, Pages 359-366

  Appenroth, Dorothea ^a   Beutinger, Ralf ^a   Lupp, Amelie ^a   Fleck, Christian ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

5 6 nephrectomy; Interstitial fibrosis; Losartan; Quinaprilat; Rat; Uranyl nitrate

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYPROLINE; LOSARTAN; QUINAPRILAT; URANYL NITRATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HEMODYNAMIC MONITORING; HISTOPATHOLOGY; IN VITRO STUDY; KIDNEY CORTEX SLICE; NEPHRECTOMY; NONHUMAN; PROTEIN URINE LEVEL; RAT; RENOVASCULAR HYPERTENSION; SINGLE DRUG DOSE;

ANIMALIA; RATTUS NORVEGICUS;

EID: 0038234891     PISSN: 09402993     EISSN: None     Source Type: Journal    
DOI: 10.1078/0940-2993-00271     Document Type: Article

References (33)

1. AMANN K, SIMONAVICIENE A, MEDWEDEWA T, et al.: Blood pressure-independent additive effects of pharmacologic blockade of the renin-angiotensin and endothelin systems on progression in a low-renin model of renal damage. J Am Soc Nephrol 2001; 12: 2572-2584.
2. AMIRI F, HADDAD G, GARCIA R: Renal angiotensin II receptor regulation and renin-angiotensin system inhibition in one-kidney, one clip hypertensive rats. J Hypertens 1999; 17: 279-286.
3. ANDERSEN S, TARNOW L, CAMBIEN F, et al.: Renoprotective effects of losartan in diabetic nephropathy: Interaction with ACE insertion/deletion genotype? Kidney Int 2002; 62: 192-198.
4. APPENROTH D, LUPP A, KRIEGSMANN J, et al.: Temporary warm ischaemia, 5/6 nephrectomy and single uranyl nitrate administration - comparison of three models intended to cause renal fibrosis in rats. Exp Toxicol Pathol 2001; 53: 316-324.
5. BEGG EJ, ROBSON RA, BAILY RR, et al.: The pharmacokinetics and pharmcodynamics of quinapril and quinaprilat in renal impairment. Br J Clin Pharmacol 1990; 30: 213-220.
6. BONNARDEAUX A, DAVIES E, JEUNEMAITRE X, et al.: Angiotensin II type 1 receptor gene polymorphism in human essential hypertension. Hypertension 1994; 24: 63-69.
7. BRADFORD M: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254.
8. BRÄUNLICH H, FLECK C, WEISE C, et al.: Stimulation of kidney function in rats of different ages injured by nephrotoxic agents. Exp Pathol 1979; 17: 486-492.
9. CRARY GS, SWAN SK, O'DONNELL MP, et al.: The angiotensin II receptor antagonist losartan reduces blood pressure but not renal injury in obese Zucker rats. J Am Soc Nephrol 1995; 6: 1295-1299.
10. ELIAHOU H, AVINOACH I, SHAMUROV M, et al.: Renoprotective effect of angiotensin II receptor antagonists in experimental chronic renal failure. Am J Nephrol 2001; 21: 78-83.
11. FOGO AB, KON V: Pathophysiology of progressive renal disease. In: NEILSON EG, COUSER WG (eds.) Immunologic renal diseases, Lippincott-Raven, Philadelphia 1997; pp. 683-704.
12. GAJDOS M, KRIVOSÍKOVÃ Z, SEBEKOVÁ K, et al.: Enalapril inhibits growth and proliferation of various tissues in rat normotensive four-sixths kidney ablation nephropathy. Kidney Blood Press Res 2000; 23: 106-112.
13. GRETZ N, MEISINGER E, STRAUCH M: Partial nephrectomy and chronic renal failure: The "mature" rat model. Contrib Nephrol 1988; 60: 46-55.
14. HANDA RK, HANDA SE, ELGEMARK MKS. Autoradiographic analysis and regulation of angiotensin receptor subtypes AT4, AT1, and AT(1 - 7) in the kidney. Am J Physiol 2001; 281: F936-F947.
15. KAPLAN HR, TAYLOR DG, OLSON SC, et al.: Quinapril - A preclinical review of the pharmacology, pharmacokinetics, and toxicology. Angiol 1989; 40: 335-350.
16. KLAHR S AND MORRISSEY J: Comparative effects of ACE inhibition and angiotensin II receptor blockade in the prevention of renal damage. Kidney Int 2002; Suppl 82: S23-S26.
17. KOHZUKI M, KAMIMOTO M, WU XM, et al.: Renal protective effect of chronic exercise and antihypertensive therapy in hypertensive rats with chronic renal failure. J Hypertens 2001; 19: 1877-1882.
18. KUGLER AR, OLSON SC SMITH DE: Tubular transport mechanisms of quinapril and quinaprilat in the isolated perfused rat kidney: effect of organic anions and cations. J Pharmacokin Biopharmaceut 1996; 24: 349-368.
19. LARIVIERE R, LEBEL M, KINGMA I, et al.: Effects of losartan and captopril on endothelin-1 production in blood vessels and glomeruli of rats with reduced renal mass. Am J Hypertens 1998; 11: 989-997.
20. MILLER JA, THAL K, SCHOLEY JW: Angiotensin II type 1 receptor gene polymorphism predicts response to losartan and angiotensin II. Kindey Int 1999; 56: 2173-2180.
21. MIYATA N, PARK F, LI XF, et al.: Distribution of angiotensin AT1 and AT2 receptor subtypes in the rat kidney. Am J Physiol 1999; 277: F437-F446.
22. MORRISSEY JJ, ISHIDOYA S, MCCRACKEN R, et al.: The effect of ACE inhibitors on the expression of matrix genes and the role of p53 and p21 (WAF1) in experimental renal fibrosis. Kidney Int 1996; Suppl 54: S83-S87.
23. NODA M, MATSUO T, FUKUDA R, et al.: Effect of candesartan cilexetil (TCV-116) in rats with chronic renal failure. Kidney Int 1999; 56: 898-909.
24. OTS M, MACKENZIE HS, TROY JL, et al.: Effects of combination therapy with enalapril and losartan on the rate of progression of renal injury in rats with 5/6 renal mass ablation. J Am Soc Nephrol 1998; 9: 224-230.
25. OTS M, PECHTER U, TAMM A: Characteristics of progressive renal disease. Review. Clin Chim Acta 2000; 297: 29-41.
26. RUIZ-ORTEGA M, GOMEZ-GARRE D, LIU XH, et al.: Quinapril decreases renal endothelin-1 expression and synthesis in a normotensive model of immune-complex nephritis. J Am Soc Nephrol 1997; 8: 756-768.
27. SMITH DE, KUGLER AR, SCHNERMANN JB: Reabsorption and metabolism of quinapril and quinaprilat in rat kidney: In vivo micropuncture studies. J Pharmaceut Sci 1995; 84: 1147-1150.
28. SPENCER K: Analytical reviews in clinical biochemistry: The estimation of creatinine. Ann Clin Biochem 1986; 23: 1-25.
29. STRATFORD MRL, WATFA RR, MURRAY C, et al.: Determination of collagen and protein turnover by high-performance liquid chromatography. J Chromatogr 1990; 529: 383-395.
30. STRUTZ F, MÜLLER GA: Interstitial pathomechanism underlying progressive tubulointerstitial damage. Kidney Blood Press Res 1999; 22: 71-80.
31. TAAL MW, CHERTOW GM, RENNKE HG, et al.: Mechanisms underlying renoprotection during renin-angiotensin system blockade. Am J Physiol 2001; 280: F343-F355.
32. WOLF G: Molecular mechanisms of angiotensin II in the kidney: emerging role in the progression of renal disease: beyond haemodynamics. Nephrol Dial Transplant 1998; 13: 1131-1142.
33. WOLTER K, FRITSCHKA E: Pharmacokinetics and pharmacodynamics of quinaprilat after low dose quinapril in patients with terminal renal failure. Europ J Clin Pharmacol 1993; 44 [Suppl 11: S 53-S 56.